|Five-Year Data from the Medtronic ENGAGE Registry Demonstrate Durable, Consistent, and Proven Outcomes in Real-World Setting|
Presented at Charing Cross, Five-Year Clinical Data from Global ENGAGE Registry
DUBLIN and LONDON - April 26, 2017 - Medtronic plc (NYSE:MDT) today reported its Endurant® II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting. The five-year ENGAGE global registry data were presented for the first time at the 2017 Charing Cross Symposium in London.
"Out to five years, the ENGAGE data showed low ARM and secondary procedure rates. This further demonstrates both the benefit of the technique used with Endurant as well as the durability of the graft itself," said ENGAGE investigator Philippe Cuypers, M.D., Ph.D., vascular surgeon, Catharina Hospital in Eindhoven, The Netherlands, who presented the data. "The clinical rigor and scope of the ENGAGE registry has made it a valuable data set that represents the types of challenging anatomies physicians encounter in daily clinical practice."
ENGAGE represents the most robust post-market registry ever initiated in the study of endovascular aortic repair (EVAR) with 79 sites in 30 countries. The ENGAGE registry was initiated less than one year post CE Mark and has clinical follow up out to 10 years, further demonstrating the Medtronic commitment to long-term clinical excellence. The goal of ENGAGE remains to gather evidence in a real-world patient population, including patients with challenging anatomy who have historically been difficult to treat, and are associated with limited eligibility for endovascular repair and higher rates of secondary interventions. A rigorous monitoring protocol has resulted in a clinical follow-up compliance of more than 90 percent and imaging compliance of more than 75 percent at five years.
As demonstrated in Prof. Hence Verhagen, M.D., Ph.D., presentation entitled "Safety Considerations with Hostile Neck 10-15mm," on April 26, 2017, Endurant continues to demonstrate durable results across a range of patient anatomies, including patients with more hostile aortic necks, which have historically been associated with limited eligibility for endovascular repair and higher rates of adverse events.
"Medtronic aims to increase access to treatment for patients with Aortic disease. This goal has been reinforced by our commitment to developing robust clinical programs - such as the ENGAGE registry - that help clinicians identify durable treatment options," said Daveen Chopra, vice president and general manager of the Aortic business in Medtronic's Cardiac and Vascular Group. "In fact, we are leveraging our strong Endurant stent graft data for a pilot risk-share program in the U.S. that has been designed to help decrease customer costs associated with secondary EVAR interventions."
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.
About the Endurant II/IIs Stent System
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.